课题基金 / 基金详情

Next generation ballistic body armour

Next generation ballistic body armour
下一代弹道防弹衣
批准号:
10011079
负责人:
金额:
$44.39万
依托单位:
依托单位国家:
英国
项目类别:
Responsive Strategy and Planning
财政年份:
2022
资助国家:
英国
项目状态:
已结题
起止时间:
2022 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
VIKELA Armour是下一代弹道防弹衣原型,利用新材料和新颖的制造方法,创造出比市场上任何其他产品更轻,更灵活,更坚固的防弹衣原型,允许穿戴者保护他们的整个身体,旨在彻底改变全球防弹衣市场,仅军事采购就价值120.2亿美元2019\。现在的防弹衣太重了。由于重量,它只能用来覆盖躯干,正因为如此,在球场上看到的大多数伤害都是在四肢。他们也制造一个尺寸适合所有的方法。据报道,68%的女兵穿着不合身的盔甲,造成了伤害或痛苦。通过这个项目,VIKELA Armour将解决传统防弹防弹衣背心的缺点,传统防弹衣背心由坚硬、沉重、高密度的材料组成,导致装甲沉重并损害其灵活性。Vikela将创造一种新的盔甲,可以很容易地调整,以适应每个用户,促进包容,减少女性用户看到的伤害。这种盔甲也将是灵活的,能够覆盖四肢,减少受伤和医疗费用。到项目结束时,Vikela将开发出经过标准认证过程的装甲。这将允许Vikela开始授权该产品并建立其收入。
英文摘要
VIKELA Armour is a next generation ballistic body armour prototype utilising new materials and novel manufacturing methods, to create a body armour prototype which is lighter, more flexible and stronger than any other product on the market, allowing wearers to protect their whole body, and aims to revolutionise the global body armour marketplace, which for military procurement alone was valued at $12.02B USD in 2019\.Current body armour is too heavy. Due to the weight it can only be used to cover the torso and because of this most injuries seen in the field are to the extremities. they are also manufactured on a one size fits all approach. This is leaving 68% of female soldiers to report wearing ill-fitting armour which caused injury or distress.Through this project, VIKELA Armour will address the drawbacks of traditional ballistic body armour vests, which are comprised of rigid and heavy, high density, materials, causing the armour to be heavy and impairing its flexibility.Vikela will create a new armour which can be easily adjusted to fit each user individually, promoting inclusion and reducing injuries seen by female users. The armour will also be flexible and able to cover the extremities reducing injuries seen and medical costs. By the end of the project Vikela will have developed armour which has undergone the standard certification process. this will allow Vikela to begin to licence the product and build its revenue.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
细胞周期蛋白依赖性激酶Cdk1介导卵母细胞第一极体重吸收致三倍体发生的调控机制研究
  • 批准号:
    82371660
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    魏喆
  • 依托单位:
Next Generation Majorana Nanowire Hybrids
二次谐波非线性光学显微成像用于前列腺癌的诊断及药物疗效初探
  • 批准号:
    30470495
  • 项目类别:
    面上项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2004
  • 负责人:
    邓小元
  • 依托单位: